Actively Recruiting
Exosomes in Rectal Cancer
Led by University of Kansas Medical Center · Updated on 2026-05-06
30
Participants Needed
1
Research Sites
520 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary aims of this study is to characterize exosomal biomarker levels in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation therapy. Compare rates of exosomal expression before during and after chemoradiation therapy with pathologic response rates at the time of APR or LAR. The researchers will also examine the functionality of these exosomes in malignant colonic organoids and mouse models of colorectal cancer.
CONDITIONS
Official Title
Exosomes in Rectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and Female Patients aged 18 and older
- Histologically proven diagnosis of rectal adenocarcinoma
- Will be receiving neoadjuvant chemoradiation therapy prior to a planned definitive surgical resection
You will not qualify if you...
- Age less than 18
- Unable or unwilling to undergo definitive surgery
- Prior history of pelvic external beam radiation, brachytherapy, or chemotherapy
- Prior history of cancer (excluding non-melanoma skin cancers)
- Immunocompromised patients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Kansas Medical Center/ Cancer Center
Kansas City, Kansas, United States, 66190
Actively Recruiting
Research Team
L
Leah K Miller, MS
CONTACT
M
Michelle Faucheux, RN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here